Literature DB >> 23536560

Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy.

Kathleen P Wilkie1, Philip Hahnfeldt.   

Abstract

Cancer in a host induces responses that increase the ability of the microenvironment to sustain the growing mass, for example, angiogenesis, but cancer cells can have varying sensitivities to these sustainability signals. Here, we show that these sensitivities are significant determinants of ultimate tumor fate, especially in response to treatments and immune interactions. We present a mathematical model of cancer-immune interactions that modifies generalized logistic growth with both immune-predation and immune-recruitment. The role of a growing environmental carrying capacity is discussed as a possible regulatory mechanism for tumor growth, and this regulation is shown to modify cancer-immune interactions and the possibility of achieving immune-induced tumor dormancy. This mathematical model qualitatively matches experimental observations of immune-induced tumor dormancy as it predicts dormancy as a transient period of growth that necessarily ends in either tumor elimination or tumor escape. As dormant tumors may exist asymptomatically and may be easier to treat with conventional therapy, an understanding of the mechanisms behind tumor dormancy may lead to new treatments aimed at prolonging the dormant state or converting an aggressive cancer to the dormant state. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23536560      PMCID: PMC3955200          DOI: 10.1158/0008-5472.CAN-12-4590

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Treatment-Induced Accelerated Human Tumor Growth.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1993-04       Impact factor: 5.934

2.  Data-driven modelling of receptor tyrosine kinase signalling networks quantifies receptor-specific potencies of PI3K- and Ras-dependent ERK activation.

Authors:  Murat Cirit; Jason M Haugh
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 3.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 4.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

Review 5.  The role of the microenvironment in mammary gland development and cancer.

Authors:  Kornelia Polyak; Raghu Kalluri
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-30       Impact factor: 10.005

Review 6.  Mathematical models of cancer dormancy.

Authors:  Karen Page; Jonathan W Uhr
Journal:  Leuk Lymphoma       Date:  2005-03

7.  Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.

Authors:  Aurore Saudemont; Abdelbasset Hamrouni; Philippe Marchetti; Jizhong Liu; Nathalie Jouy; Dominique Hetuin; Francesco Colucci; Bruno Quesnel
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 9.  Immune-mediated dormancy: an equilibrium with cancer.

Authors:  Michele W L Teng; Jeremy B Swann; Catherine M Koebel; Robert D Schreiber; Mark J Smyth
Journal:  J Leukoc Biol       Date:  2008-05-30       Impact factor: 4.962

10.  Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.

Authors:  S Y El Sharouni; H B Kal; J J Battermann
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

View more
  17 in total

1.  Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach.

Authors:  Sebastien Benzekry; Amanda Tracz; Michalis Mastri; Ryan Corbelli; Dominique Barbolosi; John M L Ebos
Journal:  Cancer Res       Date:  2015-10-28       Impact factor: 12.701

2.  (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.

Authors:  HongYue Lin; YuZhu Wu; JinPing Chen; ShuRong Huang; YangQiang Wang
Journal:  Pharm Res       Date:  2018-07-30       Impact factor: 4.200

3.  Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.

Authors:  Yana G Najjar; Patricia Rayman; Xuefei Jia; Paul G Pavicic; Brian I Rini; Charles Tannenbaum; Jennifer Ko; Samuel Haywood; Peter Cohen; Thomas Hamilton; C Marcela Diaz-Montero; James Finke
Journal:  Clin Cancer Res       Date:  2016-10-31       Impact factor: 12.531

4.  Modeling the Dichotomy of the Immune Response to Cancer: Cytotoxic Effects and Tumor-Promoting Inflammation.

Authors:  Kathleen P Wilkie; Philip Hahnfeldt
Journal:  Bull Math Biol       Date:  2017-06-05       Impact factor: 1.758

5.  An agent-based modeling framework linking inflammation and cancer using evolutionary principles: description of a generative hierarchy for the hallmarks of cancer and developing a bridge between mechanism and epidemiological data.

Authors:  Gary An; Swati Kulkarni
Journal:  Math Biosci       Date:  2014-08-01       Impact factor: 2.144

6.  Recurrence of Hepatocellular Carcinoma With Epithelial-Mesenchymal Transition After Spontaneous Regression: A Case Report.

Authors:  Shi-zhong Yang; Wei Zhang; Wei-sheng Yuan; Jia-hong Dong
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

7.  Aurora kinase A revives dormant laryngeal squamous cell carcinoma cells via FAK/PI3K/Akt pathway activation.

Authors:  Li-Yun Yang; Chang-Yu He; Xue-Hua Chen; Li-Ping Su; Bing-Ya Liu; Hao Zhang
Journal:  Oncotarget       Date:  2016-07-26

8.  Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer.

Authors:  Ying Guan; Rui Zhang; Zhibin Peng; Daming Dong; Guojun Wei; Yansong Wang
Journal:  J Bone Oncol       Date:  2017-11-01       Impact factor: 4.072

9.  Primary and metastatic tumor dormancy as a result of population heterogeneity.

Authors:  Irina Kareva
Journal:  Biol Direct       Date:  2016-08-23       Impact factor: 4.540

10.  Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.

Authors:  Marvin A Böttcher; Janka Held-Feindt; Michael Synowitz; Ralph Lucius; Arne Traulsen; Kirsten Hattermann
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.